Perrigo (PRGO) Stock Price, News & Analysis

Company Overview

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution. Its Consumer Healthcare division produces store-brand formulations for allergy relief, cold and flu, pain management, dermatology and women’s health. The Prescription Pharmaceuticals arm offers generic alternatives to branded drugs in areas such as dermatology and women’s health, while its Active Pharmaceutical Ingredients segment supplies key raw materials used by other drug manufacturers.

Founded in 1887 by Luther Perrigo in Allegan, Michigan, the company has grown through both organic innovation and strategic acquisitions, including the purchases of Paddock Laboratories and Omega Pharma. In 2013, Perrigo re-domiciled to Ireland and established its headquarters in Dublin, reflecting its expanded international footprint. Today, the company serves markets across North America, Europe, the Middle East, Africa and Asia-Pacific, operating manufacturing facilities and research centers in multiple regions. Perrigo’s commitment to product quality, regulatory compliance and sustainable manufacturing underpins its mission to deliver accessible healthcare solutions worldwide.

Key Stats

• Today's Range: $11.11 to $11.56
• 50-Day Range: $9.25 to $12.27
• 52-Week Range: $9.23 to $28.43
• Volume: 2.28 million shs
• Average Volume: 2.44 million shs
• Market Capitalization: $1.55 billion
• P/E Ratio: N/A
• Dividend Yield: 10.35%
• Price Target: $19.33
• Consensus Rating: Hold

Perrigo Stock Analysis - MarketRank™

Perrigo scored higher than 87% of companies evaluated by MarketBeat, and ranked 25th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Perrigo has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.

Upside Potential

Perrigo has a consensus price target of $19.33, representing about 72.5% upside from its current price of $11.21.

Amount of Analyst Coverage

Perrigo has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 12.15%

Earnings Growth

Earnings for Perrigo are expected to grow by 12.15% in the coming year, from $2.14 to $2.40 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Perrigo is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Perrigo is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Perrigo has a PEG Ratio of 1.31. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Perrigo has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.79% of the float of Perrigo has been sold short.

Short Interest Ratio / Days to Cover

Perrigo has a short interest ratio ("days to cover") of 6.63.

Change versus previous month

Short interest in Perrigo has recently decreased by 3.09%, indicating that investor sentiment is improving.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

Perrigo is a leading dividend payer. It pays a dividend yield of 10.34%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Perrigo has been increasing its dividend for 23 years.

Dividend Sustainability

Based on earnings estimates, Perrigo will have a dividend payout ratio of 48.33% next year. This indicates that Perrigo will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.22

News Sentiment

Perrigo has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Perrigo this week, compared to 7 articles on an average week.

Search Interest

27 people have searched for PRGO on MarketBeat in the last 30 days. This is an increase of 145% compared to the previous 30 days.

MarketBeat Follows

2 people have added Perrigo to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Perrigo insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.40% of the stock of Perrigo is held by insiders.

Percentage Held by Institutions

95.91% of the stock of Perrigo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 3/24 Dividend: 3/02/2026
• Ex-Dividend for 3/24 Dividend: 3/02/2026
• Dividend Payable: 3/24/2026
• Last Earnings: 5/06/2026
• Today: 5/24/2026
• Record date for 6/16 Dividend: 5/29/2026
• Ex-Dividend for 6/16 Dividend: 5/29/2026
• Dividend Payable: 6/16/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:PRGO
• CIK: 1585364
• Web: www.perrigo.com
• Phone: (531) 709-4000
• Fax: 269-673-9128
• Employees: 8,100
• Year Founded: 1887

Price Target and Rating

• Average Price Target for Perrigo: $19.33
• High Price Target: $23.00
• Low Price Target: $17.00
• Potential Upside/Downside: +72.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($13.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 5.24
• P/E Growth: 1.31
• Net Income: -$1.43 billion
• Net Margins: -43.50%
• Pretax Margin: -41.04%
• Return on Equity: 9.96%
• Return on Assets: 3.90%

Debt

• Debt-to-Equity Ratio: 1.45
• Current Ratio: 2.72
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $4.25 billion
• Price / Sales: 0.36
• Cash Flow: $5.29 per share
• Price / Cash Flow: 2.12
• Book Value: $18.06 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 138,370,000
• Free Float: 137,815,000
• Market Cap: $1.55 billion
• Optionable: Optionable
• Beta: 0.52